Christian E Larsen

US Patent:

7304033, Dec 4, 2007

Filed:

May 23, 2002

Appl. No.:

10/155514

Inventors:

Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/16
C07K 14/00

US Classification:

514 12, 4241341, 530350, 5303873

Abstract:

The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.

US Patent:

7829534, Nov 9, 2010

Filed:

Oct 29, 2007

Appl. No.:

11/978701

Inventors:

Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 38/16
C07K 14/705
C07K 16/46

US Classification:

514 12, 4241341, 530350, 5303873

Abstract:

The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.

US Patent:

20020031510, Mar 14, 2002

Filed:

May 22, 2001

Appl. No.:

09/862255

Inventors:

Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US

Assignee:

Bristol-Myers Squibb Company

International Classification:

A61K039/395

US Classification:

424/131100, 424/144100

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

20030007968, Jan 9, 2003

Filed:

Jan 25, 2002

Appl. No.:

10/057288

Inventors:

Christian Larsen - Atlanta GA, US
Thomas Pearson - Atlanta GA, US
Edmund Waller - Atlanta GA, US
Andrew Adams - Atlanta GA, US

International Classification:

A61K039/395
A61K031/255
A61K045/00

US Classification:

424/144100, 424/093700, 514/517000

Abstract:

Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell depleted bone marrow cells.

US Patent:

20050202011, Sep 15, 2005

Filed:

Jan 4, 2005

Appl. No.:

11/028793

Inventors:

Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Edmonds WA, US
Diane Hollenbaugh - Seattle WA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US

International Classification:

A61K039/395

US Classification:

424144100

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

20090186037, Jul 23, 2009

Filed:

Sep 10, 2008

Appl. No.:

12/207997

Inventors:

Christian P. Larsen - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US

International Classification:

A61K 39/395
A61K 38/16
A61P 37/06

US Classification:

4241441, 514 12

Abstract:

The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.

US Patent:

20110129496, Jun 2, 2011

Filed:

Aug 5, 2009

Appl. No.:

13/057057

Inventors:

Rafi Ahmed - Atlanta GA, US
Christian P. Larsen - Atlanta GA, US
Koichi Araki - Atlanta GA, US

Assignee:

EMORY UNIVERSITY - Atlanta GA

International Classification:

A61K 39/12
A61K 39/02
A61K 39/00
A61P 31/04
A61P 31/10
A61P 31/12
A61P 33/00
A61P 35/00

US Classification:

4242041, 4242341, 4242651, 4242741, 4242771

Abstract:

It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.

US Patent:

59165600, Jun 29, 1999

Filed:

Mar 20, 1997

Appl. No.:

8/821400

Inventors:

Christian P. Larsen - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA

Assignee:

Bristol-Myers Squibb Company - Pinceton NJ
Emory University - Atlanta GA

International Classification:

C07K 1628

US Classification:

4241541

Abstract:

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.